Bafna Pharmaceuticals Limited Stock price NSE India S.E.

Equities

BAFNAPH

INE878I01014

Pharmaceuticals

End-of-day quote NSE India S.E. 5-day change 1st Jan Change
- INR -.--% Intraday chart for Bafna Pharmaceuticals Limited +697.75% +207.36%
Sales 2022 851M 10.21M Sales 2023 1.15B 13.84M Capitalization 1.94B 23.27M
Net income 2022 51M 612K Net income 2023 113M 1.36M EV / Sales 2022 3.65 x
Net Debt 2022 109M 1.31M Net Debt 2023 151M 1.81M EV / Sales 2023 1.81 x
P/E ratio 2022
58.4 x
P/E ratio 2023
17.1 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 10.23%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 80-12-31
Director of Finance/CFO - -
Compliance Officer - 23-04-06
Members of the board TitleAgeSince
Chief Executive Officer 62 80-12-31
Director/Board Member 63 23-06-25
Director/Board Member - -
More insiders
Bafna Pharmaceuticals Limited is an India-based company, which is engaged in the manufacture of drugs and medicines and selling a reputed brand namely RARICAP. The Company caters to both domestic and international market. It operates in generic pharmaceutical segment. The Company manufactures 336 licensed pharmaceutical formulations and have globally registered 78 of its products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements. The Company’s subsidiary is Bafna Lifestyles Remedies Limited.
More about the company
  1. Stock
  2. Equities
  3. Stock Bafna Pharmaceuticals Limited
  4. Stock Bafna Pharmaceuticals Limited - NSE India S.E.